Company: IXHL
Filing Date: 2025-04-16
Form Type: S-1/A
Source: 0001213900-25-032577
Chunk: 3

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-16
Form: S-1/A
Chunk 3
---
 at prices related to prevailing market prices or at
privately negotiated prices. For further information regarding the possible methods by which our Common Stock may be distributed,
see “Plan of Distribution” beginning on page 20 in this prospectus. Each of the selling stockholders is an
“underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended (the “Securities
Act”).

We are not selling any securities
under this prospectus and will not receive any of the proceeds from the sale of Shares by the selling stockholders. We will likely only
receive nominal proceeds of $0.0001 per share upon the cash exercise of the Pre-Funded Warrants. Though we would receive the proceeds
for the cash exercise of the Series A Warrants per their terms, we are unlikely to receive any cash proceeds from the exercise of the
Series A Warrants as the Series A Warrants may be exercised following Stockholder Approval on a zero exercise price basis where the holder
will be eligible to receive, for each share of Common Stock issuable upon exercise of the Series A Warrant (which itself is subject to
up to a tenfold increase depending on the price of our common stock on the Release Date, as defined in the Section titled “Prospectus Summary – 2025 Private Placement” on page 1 of this prospectus), three shares of our Common Stock without the payment
of any exercise price.

As of April 11, 2025, the securities registered for resale by the selling stockholders in the registration statement of which this prospectus forms a part would represent approximately 275.5% of the 27,546,753 shares of our Common Stock outstanding and 20.1% of our total shares of Common Stock outstanding assuming the exercise of all Pre-Funded Warrants and the issuance of the maximum number of shares of Common Stock that may be issuable upon exercise of the Series A Warrants. Following and assuming our receipt of the Stockholder Approval to increase our authorized shares of Common Stock, we will be required to register an additional 282,894,619shares of our Common Stock for resale. A total of up to347,222,700 shares of Common Stock may be issuable upon exercise of the Series A Warrants. The securities to be registered for resale by the selling stockholders in the above referenced future resale registration statement and in the registration statement of which this prospectus forms a part would be approximately 1 ,